Status:
COMPLETED
Conduction Disease After Transcatheter Aortic Valve Replacement
Lead Sponsor:
Henry Ford Health System
Collaborating Sponsors:
Medtronic
Conditions:
Aortic Stenosis
Heart Block
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a prospective single center Cardiology department observational study. The study aim is to better understand the predictors of high grade conduction abnormalities associated with TAVR such tha...
Detailed Description
TAVR is a very commonly performed procedure throughout the world; it has become standard of care as the treatment for aortic stenosis and is performed in hundreds of thousands of patients annually. TA...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Signed and dated Informed Consent
- Patient that undergoes a TAVR
- Ability to complete functional assessments.
- Exclusion Criteria:
- Patients with pre-existing permanent pacemaker.
- Patient unwilling or unable to follow-up for necessary pre- and post-procedure clinical assessments.
Exclusion
Key Trial Info
Start Date :
July 16 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2022
Estimated Enrollment :
126 Patients enrolled
Trial Details
Trial ID
NCT04489095
Start Date
July 16 2020
End Date
August 1 2022
Last Update
December 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Henry Ford Health System
Detroit, Michigan, United States, 48202